User menu

Nephro-oncology: a link in evolution

Bibliographic reference Lacava, Viviana ; Coppolino, Giuseppe ; Puntorieri, Elvira ; Cernaro, Valeria ; Lupica, Rosaria ; et. al. Nephro-oncology: a link in evolution. In: Renal Failure, Vol. 37, no.8, p. 1260-1266 (2015)
Permanent URL http://hdl.handle.net/2078.1/176138
  1. Lameire Norbert H., Flombaum Carlos D., Moreau Delphine, Ronco Claudio, Acute renal failure in cancer patients, 10.1080/07853890510007205
  2. Vajdic Claire M., McDonald Stephen P., McCredie Margaret R. E., van Leeuwen Marina T., Stewart John H., Law Matthew, Chapman Jeremy R., Webster Angela C., Kaldor John M., Grulich Andrew E., Cancer Incidence Before and After Kidney Transplantation, 10.1001/jama.296.23.2823
  3. Wong G., Hayen A., Chapman J. R., Webster A. C., Wang J. J., Mitchell P., Craig J. C., Association of CKD and Cancer Risk in Older People, 10.1681/asn.2008090998
  4. Arican A, Özdemir N, Sezer S, Erten Y, Güz G, Turan M, Inanoglu I, Haberal M, Tumor markers in hemodialysis patients, 10.1016/s0041-1345(99)00846-5
  5. Maisonneuve Patrick, Agodoa Lawrence, Gellert Ryszard, Stewart John H, Buccianti Gheardo, Lowenfels Albert B, Wolf Robert A, Jones Elisabeth, Dsiney Alex PS, Briggs Douglas, McCredie Margaret, Boyle Peter, Cancer in patients on dialysis for end-stage renal disease: an international collaborative study, 10.1016/s0140-6736(99)06154-1
  6. Darmon Michael, Ciroldi Magali, Thiery Guillaume, Schlemmer Benoît, Azoulay Elie, 10.1186/cc4907
  7. Ogawa Tomoko, Niho Seiji, Nagai Shunji, Kojima Takashi, Nishimura Yoshiko, Ohe Yuichiro, Kondo Naoki, Yamaguchi Takuhiro, Endo Kazushi, Izumi Keishiro, Minami Hironobu, Moderate renal dysfunction may not require a cisplatin dose reduction: a retrospective study of cancer patients with renal impairment, 10.1007/s10147-012-0481-x
  8. Pabla N., Dong Z., Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies, 10.1038/sj.ki.5002786
  9. Sahni Vaibhav, Choudhury Devasmita, Ahmed Ziauddin, Chemotherapy-associated renal dysfunction, 10.1038/nrneph.2009.97
  10. Widemann Brigitte C., Balis Frank M., Kim AeRang, Boron Matthew, Jayaprakash Nalini, Shalabi Aiman, O'Brien Michelle, Eby Michelle, Cole Diane E., Murphy Robert F., Fox Elizabeth, Ivy Percy, Adamson Peter C., Glucarpidase, Leucovorin, and Thymidine for High-Dose Methotrexate-Induced Renal Dysfunction: Clinical and Pharmacologic Factors Affecting Outcome, 10.1200/jco.2009.25.4540
  11. Perazella M. A., Onco-Nephrology: Renal Toxicities of Chemotherapeutic Agents, 10.2215/cjn.02780312
  12. McCullough PA, Rev Cardiovasc Med., 4, S3 (2003)
  13. Lacquaniti Antonio, Buemi Francesco, Lupica Rosaria, Giardina Claudio, Murè Gabriella, Arena Adriana, Visalli Carmela, Baldari Sergio, Aloisi Carmela, Buemi Michele, Can Neutrophil Gelatinase–associated Lipocalin Help Depict Early Contrast Material–induced Nephropathy?, 10.1148/radiol.12120578
  14. Raftopoulos Harry, Diagnosis and management of hyponatremia in cancer patients, 10.1007/s00520-007-0309-9
  15. Vantyghem Marie-Christine, Balavoine Anne-Sophie, Wémeau Jean-Louis, Douillard Claire, Hyponatremia and antidiuresis syndrome, 10.1016/j.ando.2011.10.001
  16. Bolignano Davide, Coppolino Giuseppe, Criseo Manila, Campo Susanna, Romeo Adolfo, Buemi Michele, Aquaretic Agents: Whats Beyond the Treatment of Hyponatremia?, 10.2174/138161207780363040
  17. North William G., Gene regulation of vasopressin and vasopressin receptors in cancer, 10.1111/j.1469-445x.2000.tb00005.x
  18. Bolignano Davide, Medici Maria Antonietta, Coppolino Giuseppe, Sciortino Maria Teresa, Merlo Francesca Marino, Campo Susanna, Donato Valentina, Venuti Assunta, Sturiale Alessio, Zaccaria Daniela, Buemi Antoine, Lacquaniti Antonio, Buemi Michele, Aquaretic inhibits renal cancer proliferation: Role of vasopressin receptor-2 (V2-R), 10.1016/j.urolonc.2008.12.014
  19. Salahudeen Abdulla K., Doshi Simit M., Shah Pankaj, The frequency, cost, and clinical outcomes of hypernatremia in patients hospitalized to a comprehensive cancer center, 10.1007/s00520-013-1734-6
  20. Bergman Philip J., Paraneoplastic Hypercalcemia, 10.1053/j.tcam.2012.09.003
  21. Clines Gregory A., Mechanisms and treatment of hypercalcemia of malignancy : , 10.1097/med.0b013e32834b4401
  22. Janovska Z, Acta Med, 55, 111 (2012)
  23. Markowitz Glen S., Fine Paul L., Stack Jay I., Kunis Cheryl L., Radhakrishnan Jai, Palecki Winicjusz, Park Jin, Nasr Samih H., Hoh Shirley, Siegel David S., D'Agati Vivette D., Toxic acute tubular necrosis following treatment with zoledronate (Zometa), 10.1046/j.1523-1755.2003.00071.x
  24. Iguchi Kazuhiro, Tatsuda Yoshiki, Usui Shigeyuki, Hirano Kazuyuki, Pamidronate inhibits antiapoptotic bcl-2 expression through inhibition of the mevalonate pathway in prostate cancer PC-3 cells, 10.1016/j.ejphar.2010.05.010
  25. Fizazi Karim, Carducci Michael, Smith Matthew, Damião Ronaldo, Brown Janet, Karsh Lawrence, Milecki Piotr, Shore Neal, Rader Michael, Wang Huei, Jiang Qi, Tadros Sylvia, Dansey Roger, Goessl Carsten, Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study, 10.1016/s0140-6736(10)62344-6
  26. Ikesue Hiroaki, Tsuji Toshikazu, Hata Koujiro, Watanabe Hiroyuki, Mishima Kazuto, Uchida Mayako, Egashira Nobuaki, Miyamoto Toshihiro, Baba Eishi, Akashi Koichi, Takayama Koichi, Nakanishi Yoichi, Tokunaga Eriko, Okamoto Tatsuro, Maehara Yoshihiko, Yokomizo Akira, Naito Seiji, Kubo Makoto, Tanaka Masao, Masuda Satohiro, Time Course of Calcium Concentrations and Risk Factors for Hypocalcemia in Patients Receiving Denosumab for the Treatment of Bone Metastases From Cancer, 10.1177/1060028014539919
  27. Szentirmai M, West J Med., 163, 577 (1995)
  28. Cooper M. S, Gittoes N. J L, Diagnosis and management of hypocalcaemia, 10.1136/bmj.39582.589433.be
  29. Barni S. Rosti G. Pronzato P. L'anemia nel paziente oncologico. In: Kluwer Health Italia, ed.L’Anemia in oncologia. Milano, MI: Springer; 2009:1–181
  30. Buemi M, J Investig Med., 57, 892 (2009)
  31. Spiegel David, Macdougall Iain, Norris LeAnn, Qureshi Zaina, Sartor Oliver, Lai Stephen, Tallman Martin, Raisch Dennis, Smith Sheila, Silver Samuel, Murday Alanna, Armitage James, Goldsmith David, Bennett Charles, A Review of Safety, Efficacy, and Utilization of Erythropoietin, Darbepoetin, and Peginesatide for Patients with Cancer or Chronic Kidney Disease: A Report from the Southern Network on Adverse Reactions (SONAR), 10.1055/s-0032-1328884
  32. Howard Scott C., Jones Deborah P., Pui Ching-Hon, The Tumor Lysis Syndrome, 10.1056/nejmra0904569
  33. Raghavendran M, Indian J Cancer., 40, 108 (2003)
  34. Shebl Fatma M, Warren Joan L, Eggers Paul W, Engels Eric A, Cancer risk among elderly persons with end-stage renal disease: a population-based case–control study, 10.1186/1471-2369-13-65
  35. Port Friedrich K., Ragheb Nawal E., Schwartz Ann G., Hawthorne Victor M., Neoplasms in Dialysis Patients: A Population-Based Study, 10.1016/s0272-6386(89)80187-8
  36. Kamata Toshiro, Fushimi Kiyohide, Prevalence of Prostate Cancer in End-Stage Renal Disease Patients, 10.1159/000132701
  37. Marquardt P, Anticancer Res., 35, 1181 (2015)
  38. Coppolino Giuseppe, Bolignano Davide, Rivoli Laura, Mazza Giuseppe, Presta Piera, Fuiano Giorgio, Tumour Markers and Kidney Function: A Systematic Review, 10.1155/2014/647541
  39. Tong HL, Chin Med J (Engl)., 126, 274 (2013)
  40. Bruun L., Savage C., Cronin A. M., Hugosson J., Lilja H., Christensson A., Increase in percent free prostate-specific antigen in men with chronic kidney disease, 10.1093/ndt/gfn632
  41. Hsiao Ray J., Mezger Matthew S., O'Connor Daniel T., Chromogranin A in uremia: Progressive retention of immunoreactive fragments, 10.1038/ki.1990.71
  42. Drüeke Tilman B., Massy Ziad A., Beta2-Microglobulin, 10.1111/j.1525-139x.2009.00584.x
  43. Xiaofang Y., Yue Z., Xialian X., Zhibin Y., Serum tumour markers in patients with chronic kidney disease, 10.1080/00365510701282326
  44. Filella X, Int J Biol Mark., 5, 85 (1990)
  45. Zeferos Nicholas, Digenis George E., Christophoraki Mary, Alexopoulos Ioannis, Kostakis Alkis, Gyftaki Helen, Moulopoulos Spyros, Tumor Markers in Patients Undergoing Hemodialysis or Kidney Transplantation, 10.1159/000186653
  46. Menzin A, The Effect of Renal Function on Serum Levels of CA 125, 10.1006/gyno.1995.1245
  47. Lye WC, Adv Perit Dial., 10, 109 (1994)
  48. Arik N., Adam B., Akpolat T., Hasil K., Tabak S., Serum tumour markers in renal failure, 10.1007/bf02550974
  49. Maoujoud Omar, El Machtani Samira, Asseraji Mohammed, Atbib Yassine, Zajjari Yassir, Taoufik Aatif, Elbouaiti Elarabi, Zouhair Oualim, Benyahia Mohammed, Tellal Saida, Serum tumor markers in hemodialysis patients, 10.5301/ijao.5000266
  50. García-Sánchez C1, Arch Esp Urol., 66, 939 (2013)
  51. Tzitzikos G, Saudi J Kidney Dis Transplant., 21, 50 (2010)
  52. Estakhri Rasoul, Ghahramanzade Ali, Vahedi Amir, Nourazarian Alireza, Serum Levels of CA15-3, AFP, CA19-9 and CEA Tumor Markers in Cancer Care and Treatment of Patients with Impaired Renal Function on Hemodialysis, 10.7314/apjcp.2013.14.3.1597
  53. Bertolini L, Recenti Prog Med., 96, 221 (2005)
  54. Ronco Claudio, Biomarkers for acute kidney injury: is NGAL ready for clinical use?, 10.1186/s13054-014-0680-0
  55. Bolignano Davide, Coppolino Giuseppe, Lacquaniti Antonio, Nicocia Giacomo, Buemi Michele, Pathological and Prognostic Value of Urinary Neutrophil Gelatinase-Associated Lipocalin in Macroproteinuric Patients with Worsening Renal Function, 10.1159/000151665
  56. Perrin C, Clin Neuropathol., 29, 317 (2010)
  57. Bratt Tomas, Lipocalins and cancer, 10.1016/s0167-4838(00)00154-0
  58. Bauer Maret, Eickhoff Jens C., Gould Michael N., Mundhenke Christoph, Maass Nicolai, Friedl Andreas, Neutrophil gelatinase-associated lipocalin (NGAL) is a predictor of poor prognosis in human primary breast cancer, 10.1007/s10549-007-9619-3
  59. Fernandez C. A., The Matrix Metalloproteinase-9/Neutrophil Gelatinase-Associated Lipocalin Complex Plays a Role in Breast Tumor Growth and Is Present in the Urine of Breast Cancer Patients, 10.1158/1078-0432.ccr-04-2391